Keyphrases
Monoclonal Antibody
100%
Tumor Immunotherapy
100%
Agonistic Behavior
100%
Novel Epitopes
100%
Binding Site
45%
Tumor Cells
27%
Epitope
27%
Cell Apoptosis
18%
Binding Region
18%
Apoptosis
9%
Human Solid Tumors
9%
Therapeutic Agents
9%
Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)
9%
Apoptotic Pathway
9%
Cytotoxic Activity
9%
Receptor 1
9%
TRAIL Receptors
9%
TRAIL-induced Apoptosis
9%
Tumor Growth in Vivo
9%
Amino Acid Residues
9%
Extracellular Domain
9%
Agonistic
9%
Death Receptor
9%
Intrinsic Apoptosis
9%
Specific IgM
9%
Tumor Cell Apoptosis
9%
Antitumor Therapeutics
9%
Tumor Therapy
9%
Extrinsic Apoptosis
9%
Cellular Immunotherapy
9%
Amino Acid Interactions
9%
Binding Site Size
9%
Soluble TRAIL
9%
Neuroscience
Monoclonal Antibody
100%
Epitope
100%
Cancer Immunotherapy
100%
Binding Site
60%
Immunoglobulin M
30%
In Vivo
20%
Cell Signaling
10%
In Vitro
10%
Immunotherapy
10%
Amino Acid
10%
Human Monoclonal Antibody
10%
Tumor Necrosis Factor Related Apoptosis Inducing Ligand
10%
Cytotoxicity
10%
Death Receptor 4
10%
Death Receptor
10%
Intrinsic Apoptosis
10%
Essential Amino Acid
10%
Immunology and Microbiology
TNF related apoptosis inducing ligand
100%
Epitope
100%
Cancer Immunotherapy
100%
Monoclonal Antibody
66%
Binding Site
40%
Tumor Cell
26%
Immunoglobulin M
20%
Immunotherapy
6%
Tumor Necrosis Factor Related Apoptosis Inducing Ligand
6%
Cytotoxicity
6%
Signal Transduction
6%
Human Monoclonal Antibody
6%
Death Receptor
6%
Intrinsic Apoptosis
6%
Biochemistry, Genetics and Molecular Biology
TRAIL
100%
Cancer Immunotherapy
100%
Monoclonal Antibody
73%
Binding Site
40%
Immunoglobulin M
20%
Tumor Necrosis Factor
6%
Tumor Progression
6%
Signal Transduction
6%
Cytotoxicity
6%
Intrinsic Apoptosis
6%
Essential Amino Acid
6%